Abstract
The human Respiratory Syncytial Virus (hRSV) is one of the main causes of acute respiratory diseases such as bronchiolitis and pneumonia in newborns, children, and elderly. So far, there is no effective vaccine against hRSV and the only commonly offered licensed treatment, a monoclonal antibody directed at the viral fusion protein, is a costly drug that has had adverse reactions. The hRSV…